Autologous stem cell transplantation in patients who object to a blood transfusion: contribution of new pharmacological haematopoiesis support. (opens new window)

Al-Nawakil C, Quarre MC, Heshmati F, Deau B, Park S, Dreyfus F, Bouscary D, Tamburini J.

Źródło‎: Br J Haematol 2013;161(5):738-40.

Indeks‎: PubMed 23480574

DOI‎: 10.1111/bjh.12284

https://www.ncbi.nlm.nih.gov/pubmed/23480574 (opens new window)

A multicenter study of romiplostim for chemotherapy-induced thrombocytopenia in solid tumors and hematologic malignancies. (opens new window)

Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter DJ

Źródło‎: Haematologica 2021;106(4):1148-57.

Indeks‎: PubMed 32499239

DOI‎: 10.3324/haematol.2020.251900

https://www.ncbi.nlm.nih.gov/pubmed/32499239 (opens new window)

The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. (opens new window)

Aribi A, Kantarjian H, Koller C, Thomas D, Faderl S, Garcia-Manero G, Cortes J.

Źródło‎: Cancer 2008;113(6):1338-43.

Indeks‎: PubMed 18629842

DOI‎: 10.1002/cncr.23718

https://www.ncbi.nlm.nih.gov/pubmed/18629842 (opens new window)

Romiplostim efficacy in an acute myeloid leukemia patient with transfusion refractory thrombocytopenia. (opens new window)

Berthelot-Richer M, Boilard B, Morin A, Bolduc B, Beauregard P, Kotb R.

Źródło‎: Transfusion 2012;52(4):739-41.

Indeks‎: PubMed 22082044

DOI‎: 10.1111/j.1537-2995.2011.03382.x

https://www.ncbi.nlm.nih.gov/pubmed/22082044 (opens new window)

The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes. (opens new window)

Bhatia M, Davenport V, Cairo MS.

Źródło‎: Leuk Lymphoma 2007;48(1):9-15.

Indeks‎: PubMed 17325843

DOI‎: 10.1080/10428190600909115

https://www.ncbi.nlm.nih.gov/pubmed/17325843 (opens new window)

Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide. (opens new window)

Chawla SP, Staddon A, Hendifar A, Messam CA, Patwardhan R, Kamel YM.

Źródło‎: BMC Cancer 2013;13:121.

Indeks‎: PubMed 23497336

DOI‎: 10.1186/1471-2407-13-121

https://www.ncbi.nlm.nih.gov/pubmed/23497336 (opens new window)

Efficacy of romiplostim in the treatment of chemotherapy induced thrombocytopenia (CIT) in a patient with mantle cell lymphoma. (opens new window)

Demeter J, Istenes I, Fodor A, Paksi M, Dombi P, Valasinyószki E, Csomor J, Matolcsy A, Nagy ZG.

Źródło‎: Pathol Oncol Res 2011;17(1):141-3.

Indeks‎: PubMed 20628840

DOI‎: 10.1007/s12253-010-9276-4

https://www.ncbi.nlm.nih.gov/pubmed/20628840 (opens new window)

Eltrombopag for radiation-induced thrombocytopenia in a glioblastoma patient. (opens new window)

Duic JP, Grewal J, McConie K, Staszewski H, Haas J, Kesari S.

Źródło‎: J Neurooncol 2012;106(2):427-9.

Indeks‎: PubMed 21833801

DOI‎: 10.1007/s11060-011-0675-5

https://www.ncbi.nlm.nih.gov/pubmed/21833801 (opens new window)

Recombinant human interleukin 11 and bacterial infection in patients with haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. (opens new window)

Ellis M, Zwaan F, Hedström U, Poynton C, Kristensen J, Jumaa P, Wassell J, al-Ramadi B.

Źródło‎: Lancet 2003;361(9354):275-80.

Indeks‎: PubMed 12559860

https://www.ncbi.nlm.nih.gov/pubmed/12559860 (opens new window)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (opens new window)

Ford PA, Grant SJ, Mick R, Keck G.

Źródło‎: J Clin Oncol 2015;33(15):1674-9.

Indeks‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (opens new window)

Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors. (opens new window)

Gao Y, Liu Q, Shen Y, Li Y, Shao K, Ye B, Shen Y, Zhou Y, Wu D

Źródło‎: Platelets. 2022 3;33(7):1024-1030.

Indeks‎: PubMed 35040375

DOI‎: 10.1080/09537104.2022.2026910

https://pubmed.ncbi.nlm.nih.gov/35040375/ (opens new window)

Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (opens new window)

Giagounidis A, Mufti GJ, Fenaux P, Sekeres MA, Szer J, Platzbecker U, Kuendgen A, Gaidano G, Wiktor-Jedrzejczak W, Hu K, Woodard P, Yang AS, Kantarjian HM.

Źródło‎: Cancer 2014;120(12):1838-46.

Indeks‎: PubMed 24706489

DOI‎: 10.1002/cncr.28663

https://www.ncbi.nlm.nih.gov/pubmed/24706489 (opens new window)

A randomized controlled trial of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving decitabine. (opens new window)

Greenberg PL, Garcia-Manero G, Moore M, Damon L, Roboz G, Hu K, Yang AS, Franklin J.

Źródło‎: Leuk Lymphoma 2013;54(2):321-8.

Indeks‎: PubMed 22906162

DOI‎: 10.3109/10428194.2012.713477

https://www.ncbi.nlm.nih.gov/pubmed/22906162 (opens new window)

Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. (opens new window)

Gudbrandsdottir S, Frederiksen H, Hasselbalch H.

Źródło‎: Platelets 2012;23(6):423-9.

Indeks‎: PubMed 22185370

DOI‎: 10.3109/09537104.2011.634931

https://www.ncbi.nlm.nih.gov/pubmed/22185370 (opens new window)

Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial. (opens new window)

Han TT, Xu LP, Liu DH, Liu KY, Wang FR, Wang Y, Yan CH, Chen YH, Sun YQ, Ji Y, Wang JZ, Zhang XH, Huang XJ.

Źródło‎: Ann Hematol 2015;94(1):117-28.

Indeks‎: PubMed 25069650

DOI‎: 10.1007/s00277-014-2158-1

https://www.ncbi.nlm.nih.gov/pubmed/25069650 (opens new window)

The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma. (opens new window)

Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.

Źródło‎: J Hematol Oncol 2015;8:37.

Indeks‎: PubMed 25886818

DOI‎: 10.1186/s13045-015-0136-2

https://www.ncbi.nlm.nih.gov/pubmed/25886818 (opens new window)

Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. (opens new window)

Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P, Shammo J, Siegel R, Hu K, Franklin J, Berger DP.

Źródło‎: J Clin Oncol 2010;28(3):437-44.

Indeks‎: PubMed 20008626

DOI‎: 10.1200/JCO.2009.24.7999

https://www.ncbi.nlm.nih.gov/pubmed/20008626 (opens new window)

The use of simple patient blood management strategies as an alternative to platelet and red cell transfusion in autologous stem cell transplant. (opens new window)

Locantore-Ford P, Grant SJ, Keck G.

Źródło‎: Blood 2013;122(21):2140.

https://www.bloodjournal.org/content/122/21/2140 (opens new window)

The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. (opens new window)

Loo M, Beguin Y.

Źródło‎: Blood 1999;93(10):3286-93.

Indeks‎: PubMed 10233880

https://www.ncbi.nlm.nih.gov/pubmed/10233880 (opens new window)

A single center experience with romiplostim for the management of chemotherapy-induced thrombocytopenia. (opens new window)

Miao J, Leblebjian H, Scullion B, Parnes A

Źródło‎: Am J Hematol 2018;93(4):E86-E88.

Indeks‎: PubMed 29274130

DOI‎: 10.1002/ajh.25022

https://www.ncbi.nlm.nih.gov/pubmed/29274130 (opens new window)

Pharmacological therapies to minimise platelet transfusion. (opens new window)

Norfolk DR, Seghatchian J.

Źródło‎: Transfus Sci 2000;22(3):149-53.

Indeks‎: PubMed 10831916

https://www.ncbi.nlm.nih.gov/pubmed/10831916 (opens new window)

Romiplostim for management of chemotherapy-induced thrombocytopenia. (opens new window)

Parameswaran R, Lunning M, Mantha S, Devlin S, Hamilton A, Schwartz G, Soff G.

Źródło‎: Support Care Cancer 2014;22(5):1217-22.

Indeks‎: PubMed 24414994

DOI‎: 10.1007/s00520-013-2074-2

https://www.ncbi.nlm.nih.gov/pubmed/24414994 (opens new window)

Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders. (opens new window)

Pathak S, Roth M, Verma A, Steidl U.

Źródło‎: Expert Opin Drug Metab Toxicol 2013;9(12):1667-75.

Indeks‎: PubMed 24215532

DOI‎: 10.1517/17425255.2013.858119

https://www.ncbi.nlm.nih.gov/pubmed/24215532 (opens new window)

High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors. (opens new window)

Perol L, Grignano E, Contejean A, Gastaud L, Legoff M, Franchi P, Deau-Fischer B, Willems L, Bouscary D, Tamburini J

Źródło‎: Leuk Lymphoma. 2019;60(9):2324-7.

Indeks‎: PubMed 30773115

DOI‎: 10.1080/10428194.2019.1577414

https://www.ncbi.nlm.nih.gov/pubmed/30773115 (opens new window)

Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial. (opens new window)

Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A.

Źródło‎: Lancet Haematol 2015;2(10):e417-26.

Indeks‎: PubMed 26686043

https://www.ncbi.nlm.nih.gov/pubmed/26686043 (opens new window)

Romiplostim for delayed platelet recovery and secondary thrombocytopenia following allogeneic stem cell transplantation. (opens new window)

Poon LM, Di Stasi A, Popat U, Champlin RE, Ciurea SO.

Źródło‎: Am J Blood Res 2013;3(3):260-4.

Indeks‎: PubMed 23997988

https://www.ncbi.nlm.nih.gov/pubmed/23997988 (opens new window)

Safety and efficacy of eltrombopag in post-hematopoietic stem cell transplantation (HSCT) thrombocytopenia. (opens new window)

Raut SS, Shah SA, Sharanangat VV, Shah KM, Patel KA, Anand AS, Talati SS, Panchal HP, Patel AA, Parikh SK, Shukla SN.

Źródło‎: Indian J Hematol Blood Transfus 2015;31(4):413-5.

Indeks‎: PubMed 26306064

DOI‎: 10.1007/s12288-014-0491-0

https://www.ncbi.nlm.nih.gov/pubmed/26306064 (opens new window)

Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. (opens new window)

Reese JA, Li X, Hauben M, Aster RH, Bougie DW, Curtis BR, George JN, Vesely SK.

Źródło‎: Blood 2010;116(12):2127-33.

Indeks‎: PubMed 20530792

DOI‎: 10.1182/blood-2010-03-276691

https://www.ncbi.nlm.nih.gov/pubmed/20530792 (opens new window)

Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. (opens new window)

Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U.

Źródło‎: Blood 2012;120(2):386-94.

Indeks‎: PubMed 22627766

DOI‎: 10.1182/blood-2011-12-399667

https://www.ncbi.nlm.nih.gov/pubmed/22627766 (opens new window)

Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. (opens new window)

Sekeres MA, Kantarjian H, Fenaux P, Becker P, Boruchov A, Guerci-Bresler A, Hu K, Franklin J, Wang YM, Berger D.

Źródło‎: Cancer 2011;117(5):992-1000.

Indeks‎: PubMed 20945323

DOI‎: 10.1002/cncr.25545

https://www.ncbi.nlm.nih.gov/pubmed/20945323 (opens new window)

Romiplostim treatment of chemotherapy-induced thrombocytopenia. (opens new window)

Soff GA, Miao Y, Bendheim G, Batista J, Mones JV, Parameswaran R, Wilkins CR, Devlin SM, Abou-Alfa GK, Cercek A, Kemeny NE, Sarasohn DM, Mantha S

Źródło‎: J Clin Oncol 2019;37(31):2892-8.

Indeks‎: PubMed 31545663

DOI‎: 10.1200/JCO.18.01931

https://www.ncbi.nlm.nih.gov/pubmed/31545663 (opens new window)

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. (opens new window)

Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, Kabrna E, Geissler K, Jilma B.

Źródło‎: Blood 2000;95(9):2983-9.

Indeks‎: PubMed 10779449

https://www.ncbi.nlm.nih.gov/pubmed/10779449 (opens new window)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. (opens new window)

Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström-Lindberg E, Cherif H.

Źródło‎: Eur J Haematol 2014;93(5):439-45.

Indeks‎: PubMed 24853277

DOI‎: 10.1111/ejh.12383

https://www.ncbi.nlm.nih.gov/pubmed/24853277 (opens new window)

Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. (opens new window)

Tanaka T, Inamoto Y, Yamashita T, Fuji S, Okinaka K, Kurosawa S, Kim SW, Tanosaki R, Fukuda T.

Źródło‎: Biol Blood Marrow Transplant 2016;22(5):919-24.

Indeks‎: PubMed 26785333

DOI‎: 10.1016/j.bbmt.2016.01.018

https://www.ncbi.nlm.nih.gov/pubmed/26785333 (opens new window)

Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience. (opens new window)

Tsimberidou AM, Giles FJ, Khouri I, Bueso-Ramos C, Pilat S, Thomas DA, Cortes J, Kurzrock R.

Źródło‎: Ann Oncol 2005;16(1):139-45.

Indeks‎: PubMed 15598951

DOI‎: 10.1093/annonc/mdi007

https://www.ncbi.nlm.nih.gov/pubmed/15598951 (opens new window)

A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide. (opens new window)

Wang ES, Lyons RM, Larson RA, Gandhi S, Liu D, Matei C, Scott B, Hu K, Yang AS.

Źródło‎: J Hematol Oncol 2012;5:71.

Indeks‎: PubMed 23190430

DOI‎: 10.1186/1756-8722-5-71

https://www.ncbi.nlm.nih.gov/pubmed/23190430 (opens new window)

Romiplostim for chemotherapy-induced thrombocytopenia: efficacy and safety of extended use. (opens new window)

Wilkins CR, Ortiz J, Gilbert LJ, Yin S, Mones JV, Parameswaran R, Mantha S, Soff GA

Źródło‎: Res Pract Thromb Haemost. 2022;6(3):e12701.

Indeks‎: PubMed 35582038

DOI‎: 10.1002/rth2.12701

https://pubmed.ncbi.nlm.nih.gov/35582038/ (opens new window)

Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. (opens new window)

Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.

Źródło‎: Blood 2009;114(18):3899-908.

Indeks‎: PubMed 19710504

DOI‎: 10.1182/blood-2009-04-219493

https://www.ncbi.nlm.nih.gov/pubmed/19710504 (opens new window)